What's in Research in Real-Life Ltd's pipeline?

Research in Real-Life Ltd has 11 drugs in our index: 4 marketed, 0 filed, 0 in Phase 3, 7 in Phase 2, 0 in Phase 1.

Which companies overlap with Research in Real-Life Ltd's portfolio?

Top competitors by shared drug class: GlaxoSmithKline, Teva Branded Pharmaceutical Products R&D, Inc., AstraZeneca, University of Chicago, Chiesi Farmaceutici S.p.A..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/research-in-real-life-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Research in Real-Life Ltd — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Research in Real-Life Ltd pipeline: 4 marketed, 0 filed, 0 Phase 3, 7 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

4 marketed 0 filed 0 Phase 3 7 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Fluticasone 250/salmeterol 25	Fluticasone 250/salmeterol 25	marketed	Inhaled corticosteroid/long-acting beta-2 agonist combination	Glucocorticoid receptor (fluticasone); beta-2 adrenergic receptor (salmeterol)	Respiratory
Fluticasone 125/formoterol 5	Fluticasone 125/formoterol 5	marketed	Inhaled corticosteroid/long-acting beta-2 agonist combination	Glucocorticoid receptor (fluticasone); beta-2 adrenergic receptor (formoterol)	Respiratory
Qvar (100 mcg)	Qvar (100 mcg)	marketed	Inhaled corticosteroid (ICS)	Glucocorticoid receptor	Respiratory / Pulmonology
Fluticasone 250/formoterol 10	Fluticasone 250/formoterol 10	marketed	Inhaled corticosteroid/long-acting beta-2 agonist combination	Glucocorticoid receptor (fluticasone); beta-2 adrenergic receptor (formoterol)	Respiratory

Therapeutic area mix

Respiratory · 8
Respiratory / Pulmonology · 2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

GlaxoSmithKline · 5 shared drug classes
Teva Branded Pharmaceutical Products R&D, Inc. · 4 shared drug classes
AstraZeneca · 4 shared drug classes
University of Chicago · 3 shared drug classes
Chiesi Farmaceutici S.p.A. · 3 shared drug classes
Johns Hopkins University · 3 shared drug classes
SkyePharma AG · 3 shared drug classes
Istituto per la Ricerca e l'Innovazione Biomedica · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Research in Real-Life Ltd:

Cite this brief

Drug Landscape (2026). Research in Real-Life Ltd — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/research-in-real-life-ltd. Accessed 2026-05-16.